Document Detail

Relationship of the antihypertensive effect of vasopressin withdrawal to sodium excretion in the Doca-salt hypertensive rat.
MedLine Citation:
PMID:  8261688     Owner:  NLM     Status:  MEDLINE    
Arterial pressure, sodium excretion, urine output, and plasma atrial natriuretic peptide (ANP) concentrations were measured before, during, and after a 3-h i.v. infusion of arginine-vasopressin (vasopressin; 20 ng/kg/min) in conscious Doca-salt hypertensive rats. Arterial pressure was 166 +/- 8 mm Hg before the infusion of vasopressin; in comparison, pressure was only 130 +/- 4 mm Hg 5 h after stopping the infusion. The fall in pressure after withdrawal of an equipressor dose of phenylephrine in hypertensive animals was much less. In sham normotensive rats, pressure did not fall below control levels after stopping either the vasopressin or phenylephrine infusion. Sodium excretion rates were higher during infusions of vasopressin than during phenylephrine infusions. However, the elevations observed during vasopressin were similar in the hypertensive (25.3 +/- 4.9 mumol/kg/min) and normotensive (22.9 +/- 2.7 mumol/kg/min) groups. Urinary output increased to a greater extent in the hypertensive rats during the infusions of both vasopressin and phenylephrine, but the increases were similar for the 2 pressor agents. Plasma levels of ANP were elevated during the infusions of vasopressin in the normotensive rats, but not in hypertensive rats. The results indicate that the fall in pressure associated with cessation of a pressor dose of vasopressin appears specific to the hypertensive state, and relatively specific to vasopressin. This withdrawal-induced antihypertensive phenomenon (WAP) does not appear to be due solely to the preceding natriuresis and diuresis during the infusion of vasopressin. However, because the hypertensive animal may be more sensitive to a given degree of sodium loss, the possibility that the natriuresis could play a contributing or permissive role cannot be excluded.
H Wang; N Wilson; J R McNeill
Related Documents :
25224508 - Reduced pressure for fewer pressure ulcers: can real-time feedback of interface pressur...
9719148 - Cardiac remodelling in experimental renal failure--an immunohistochemical study.
19816038 - Gonadectomy influences blood pressure through the kallikrein-kinin system.
11178308 - The effects of housing enrichment on cardiovascular parameters in spontaneously hyperte...
8412338 - Plasma insulin and blood pressure response to oral glucose tolerance test in young bord...
12834848 - High pressure induces the formation of aggregation-prone states of proteins under reduc...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical and investigative medicine. Médecine clinique et experimentale     Volume:  16     ISSN:  0147-958X     ISO Abbreviation:  Clin Invest Med     Publication Date:  1993 Oct 
Date Detail:
Created Date:  1994-01-24     Completed Date:  1994-01-24     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7804071     Medline TA:  Clin Invest Med     Country:  CANADA    
Other Details:
Languages:  eng     Pagination:  348-57     Citation Subset:  IM    
Department of Pharmacology, Faculty of Medicine, University of Saskatchewan, Saskatoon.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Atrial Natriuretic Factor / blood
Blood Pressure
Hypertension / chemically induced,  physiopathology*
Osmolar Concentration
Rats, Sprague-Dawley
Sodium / blood
Vasopressins / administration & dosage*,  physiology
Reg. No./Substance:
11000-17-2/Vasopressins; 64-85-7/Desoxycorticosterone; 7440-23-5/Sodium; 85637-73-6/Atrial Natriuretic Factor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Inhibition of HIV-1 replication by daunorubicin.
Next Document:  Carrier detection and prenatal diagnosis of hemoglobinopathies in Ontario.